UK: "We Love London!": Big Pharma Choose English Law And Courts To Resolve Foreign Dispute

Last Updated: 9 April 2018
Article by Paul A. Harris

Earlier in 2017, an eminent US Mid-West IP lawyer explained to me why he considered the English Courts (whether part of the UPC or not) were in a strong position to deal with global disputes (and IP particularly). First, we have specialist IP judges. Second, because a considerable number of IP contracts had exclusive English law and jurisdiction clauses. His point was that this gave clients a degree of certainty about the speed and quality of judgments. In the modern commercial world, waiting for 2 or more years for trial let alone judgment is not acceptable, and could potentially irreparably harm a business.

It was no surprise to me, then, that the decision in Teva Pharma-Produtos Farmaceuticos Lda v Astrazeneca-Produtos Farmaceuticos Lda [2017] EWCA Civ 2135 (handed down on 21st December 2017) continued this growing trend of multi-nationals choosing to litigate in English Courts, and in relation both to foreign and English law contracts. It followed on from the decision in Merck KGaA v Merck Sharp & Dohme Corp [2017] EWCA Civ 1834, and was emulated in a decision handed down the same day as the Teva decision in The Black & Decker Corporation v Dvize bv [2017] EWHC 3387 (Pat) (in which I and the team at Venner Shipley acted). In these cases, issues of German contract law construction, and that of Maryland law, were considered.

"Westminster Abbey, the Tower Big Ben, the rosy red cheeks of the little children...."

In Teva, the appellant was the Portuguese company in the Teva Group, and the first and second respondents were the Portuguese arm of the AstraZeneca Group (and licensee), and the Japanese proprietor of the patent in issue (EP0521471 – the 'Patent' - which related to rosuvastatin an inhibitor of cholesterol production). The Patent expired on 30 June 2012. However, AstraZeneca eventually obtained in November 2013, a SPC which was to expire on 3 July 2017.

In January 2012, Teva obtained marketing authorisation from the Portuguese authority, Infarmed, for their generic rosuvastatin product. AstraZeneca commenced proceedings in the Portuguese Administrative Court against Infarmed (including Teva) on 31 July 2012. By the end of January 2013, AstraZeneca considered Teva would launch their generic product imminently, and sought a preliminary injunction under the SPC. Teva launched their product in Portugal on 1 February 2013. Following correspondence between the parties, a Settlement Agreement dated 25 February 2013 was entered into in which Teva and their affiliates were entitled to use, sell, market, distribute etc., the generic product in Portugal from 3 July 2017 onwards.

However, to complicate matters further, AstraZeneca sought a further extension of the SPC by way of a Paediatric Extension ('PE'). PEs are designed to address the concern that pharmaceutical products used to treat children were not appropriately authorised. They provide for an extension of six months to the term of an SPC, provided certain conditions are met.

An application for a PE must be filed no later than two years before the expiry of the SPC on which it is based. At the time of the Settlement Agreement, certain details needed for the PE were public, but it was uncertain whether it would be completed in time to meet the deadline for a PE. Eventually, a PE was granted which extended the term of the SPC to 29 December 2017.

Relying on the PE, on 28 April 2017 AstraZeneca commenced proceedings against Teva in Portugal, seeking to prevent Teva from selling their generic product before 29 December 2017.

As a result, Teva commenced the English proceedings against AstraZeneca, seeking expedited relief based on the Settlement Agreement and that they were entitled, irrespective of the PE, to sell product in Portugal after 3 July 2017.

"No hitting below the belt"

The key terms of the Settlement Agreement were:

Recitals (vi) and (vii) which stated:

"(vi) Given the existence of the Patent the Parties wish to avoid the costs, risks, expenses and time which would be associated with any disputes relating to the said Patent, including the Proceedings, and wish to enter into a negotiated and consensual agreement terminating and/or preventing such disputes.

(vii) Accordingly, the Parties have agreed to resolve/prevent such disputes between them on and subject to the terms set out below."

Clause 2.6, being a general release in the following terms:

"2.6. Subject to clause 2.1 (d) and (h), as of the Effective Date, Patentee irrevocably releases and forever discharges Teva and its customers in relation to any claims, rights, demands or damages arising from the use, importation, storage, offer for sale, sale, marketing, distribution of the Teva Product in or for Portugal other than in breach of this Agreement."

There was also clause 2.7 which contained an undertaking by Teva not to sell etc. their generic product before various dates, the most important of which was 3 July 2017.

Teva's argument was that the general release related to any claims. AstraZeneca's construction was that there was a restriction in the Settlement Agreement, which would include the basic patent and the SPC, but not the PE. Accordingly, they could still rely on the PE. The judge agreed that the underlying subject matter of the Settlement Agreement was to be considered. If not, Teva would be given a 'windfall' since they had obtained a marketing authorisation, and would be able to sell, despite the PE, and compete with AstraZeneca. Teva therefore failed on the basis the general release did not include claims relating to the PE. Teva appealed the decision.

"London calling"

Teva made three arguments as to why the judge fell into error:

  1. He lost sight of the principle that commercial common sense is not to be invoked retrospectively. The mere fact that a contractual arrangement, if interpreted according to its natural language, has worked out badly, or even disastrously, for one of the parties is not a reason for departing from the natural language;
  2. His approach ignored that the purpose of interpretation is to identify what the parties have agreed, not what the court thinks that they should have agreed;
  3. Previous cases of general release clauses considered the object of interpretation was that the release should extend to any claims which might later come to light, as the parties wanted to achieve finality. The mere fact that the parties were unaware of the particular claim was not a reason for excluding it from the scope of the release. The risk that further claims might later emerge was a risk the person giving the release took upon himself.

It mattered not that at the date of the Settlement Agreement the PE had not actually been achieved, since it was known to the parties it could be, and the judge was wrong to ignore this. AstraZeneca's argument was the judge's interpretation was correct.

The Court of Appeal concluded Teva were correct. They pointed out the judge acknowledged that the PE extended the SPC, and was not any separate right. Therefore, as the general release specifically covered the SPC, it also covered the PE. Accordingly, Teva could sell its generic product after 3 July and it was not a breach of the Settlement Agreement. The effect of this is also that AstraZeneca were wrong to bring the latest Portuguese proceedings.

View from the London Eye

As all IP lawyers know, hindsight is to be avoided particularly when considering novelty and obviousness. Commercial IP lawyers should also resist the temptation of using knowledge learned at a later date when considering what an agreement's terms were intended to cover and the effect on the parties.

To some extent not only do we have to be lawyers, we have to be astrologists too, and gaze into that legal crystal ball to predict the future. Well, maybe not; there are certain limits on our collective talents after all. But at least English law and Courts give greater predictability than most. It is, therefore, why businesses love London!

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions